Xencor reported Q2 2026 financial results and announced that data from XmAb819 expansion cohorts in clear cell renal cell carcinoma will be presented at ESMO 2026; additionally, the company initiated a first-in-human study for its first xenlock bispecific antibody, XmAb412.